Literature DB >> 10584762

Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder.

R A Emsley1, P P Oosthuizen, A F Joubert, M C Roberts, D J Stein.   

Abstract

BACKGROUND: Symptoms of depression and anxiety are frequently encountered in the course of schizophrenia and are of considerable clinical importance. They may compromise social and vocational functioning, and they are associated with an increased risk of relapse and suicide. Various treatment approaches have been reported to be successful.
METHOD: The sample comprised 177 patients with DSM-III-R or DSM-IV schizophrenia or schizophreniform disorder who were participants in multinational clinical drug trials at our academic psychiatric unit over a 7-year period and who were assessed by means of the Positive and Negative Syndrome Scale (PANSS). Analysis was performed on baseline PANSS scores. The depression/anxiety score was compared in the men and women, first-episode and multiple-episode patients, and those with predominantly positive and negative syndromes. Correlations were sought between depression/anxiety scores and age, total PANSS score, positive score, negative score, general psychopathology score, and treatment outcome. Multivariate analysis was applied to determine contributions of individual variables toward depression/anxiety and outcome scores.
RESULTS: Depression and anxiety symptoms were more severe in women (p = .007), first-episode patients (p = .02), and those with predominantly positive symptoms (p < .0001). Depression/anxiety scores were significantly correlated to age (r = -0.31, p < .0001), PANSS positive scores (r = 0.39, p < .0001), and treatment outcome (r = 0.25, p = .006). Multivariate analysis bore out these results, with the exception that first episode was not a significant predictor of depression and anxiety scores.
CONCLUSION: PANSS depressive/anxiety scores were generally low in our sample, perhaps because patients with schizoaffective disorder were excluded. The finding that these symptoms were more prominent in women and first-episode patients is in keeping with previous literature. The higher scores in first-episode patients are likely due to the higher positive symptom scores in these patients. The association between depressive/anxiety scores and positive symptoms but not with negative symptoms points to a specific relationship between affective symptoms and the positive symptom domain of schizophrenia. The presence of depressive and anxiety symptoms may predict a more favorable outcome to treatment, although this may only apply to the acute exacerbations of the illness.

Entities:  

Mesh:

Year:  1999        PMID: 10584762     DOI: 10.4088/jcp.v60n1105

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  22 in total

1.  The dimensional structure of the Wisconsin Schizotypy Scales: factor identification and construct validity.

Authors:  Thomas R Kwapil; Neus Barrantes-Vidal; Paul J Silvia
Journal:  Schizophr Bull       Date:  2007-09-03       Impact factor: 9.306

2.  Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia.

Authors:  Wolfram An der Heiden; Anne Leber; Heinz Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-04-23       Impact factor: 5.270

3.  Depression in the long-term course of schizophrenia.

Authors:  Wolfram an der Heiden; Regina Könnecke; Kurt Maurer; Daniel Ropeter; Heinz Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

Review 4.  Anxiety in Patients with Schizophrenia: Epidemiology and Management.

Authors:  Henk Temmingh; Dan J Stein
Journal:  CNS Drugs       Date:  2015       Impact factor: 5.749

5.  Transdiagnostic neural markers of emotion-cognition interaction in psychotic disorders.

Authors:  Amri Sabharwal; Akos Szekely; Roman Kotov; Prerona Mukherjee; Hoi-Chung Leung; Deanna M Barch; Aprajita Mohanty
Journal:  J Abnorm Psychol       Date:  2016-09-12

6.  Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia.

Authors:  Buranee Kanchanatawan; Solaphat Hemrungrojn; Supaksorn Thika; Sunee Sirivichayakul; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-09-05       Impact factor: 5.590

7.  Online Communication about Depression and Anxiety among Twitter Users with Schizophrenia: Preliminary Findings to Inform a Digital Phenotype Using Social Media.

Authors:  Yulin Hswen; John A Naslund; John S Brownstein; Jared B Hawkins
Journal:  Psychiatr Q       Date:  2018-09

8.  Disorganization/cognitive and negative symptom dimensions in the at-risk mental state predict subsequent transition to psychosis.

Authors:  Arsime Demjaha; Lucia Valmaggia; Daniel Stahl; Majella Byrne; Philip McGuire
Journal:  Schizophr Bull       Date:  2010-08-12       Impact factor: 9.306

9.  Assessment of trait and state aspects of depression in schizophrenia.

Authors:  Joshua Chiappelli; Katie L Nugent; Kavita Thangavelu; Katherine Searcy; L Elliot Hong
Journal:  Schizophr Bull       Date:  2013-05-17       Impact factor: 9.306

10.  Structural differences within negative and depressive syndrome dimensions in schizophrenia, organic brain disease, and major depression: A confirmatory factor analysis of the positive and negative syndrome scale.

Authors:  Daniel P Eisenberg; Dmitry B Aniskin; Leonard White; Judith A Stein; Philip D Harvey; Igor I Galynker
Journal:  Psychopathology       Date:  2009-05-16       Impact factor: 1.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.